Protagonist Therapeutics (PTGX) Other financing activities (2016 - 2026)

Protagonist Therapeutics has reported Other financing activities for 11 years, with the latest figure at $23.4 million in Q1 2026.

• Quarterly Other financing activities rose 96.06% year-over-year to $23.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (up 13.8% YoY) and the FY2025 annual result came in at $23.3 million, down 11.76% from the prior year.
• Other financing activities advanced to $23.4 million in Q1 2026 per PTGX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Other financing activities peaked at $23.4 million in Q1 2026 and troughed at -$3.7 million in Q4 2023.
• A 5-year average of $4.6 million and a median of $2.6 million in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2023 and 2024: Other financing activities tumbled 768.35% in 2023, then surged 1080.31% in 2024.
• Over 5 years, Other financing activities stood at $553000.0 in 2022, then plunged by 768.35% to -$3.7 million in 2023, then surged by 209.06% to $4.0 million in 2024, then decreased by 29.62% to $2.8 million in 2025, then surged by 723.9% to $23.4 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $23.4 million, $2.8 million, and $5.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.